Basit Ali Chaudhry

Dr. Basit Ali Chaudhry

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Cephalalgia
Verified
Journal Article
Open access
BCBasit Ali Chaudhry
Basit Ali Chaudhry
SYSamaira Younis
Samaira Younis
RMRoberta Messina
Roberta Messina
DGDavid García-Azorín
David García-Azorín
NKNazia Karsan
Nazia Karsan
FAFaisal Mohammad Amin
Faisal Mohammad Amin
Background: Structural imaging offers insight into migraine pathogenesis. Magnetic resonance imaging (MRI) morphometry plays a crucial role in identifying these alterations, yet the clinical significance remains debated. While gray matter volume and cortical curvature are commonly analyzed, cortical thickness offers a more direct measure of cytoarchitectural differences and neuroplastic changes in migraine. Advanced structural MRI techniques, including surface-based morphometry and voxel-based morphometry, have provided insights into cortical thickness alterations in migraine. These methods enable high-resolution assessment of brain morphometry, revealing dynamic changes associated with migraine phases and treatment. Methods: This narrative review synthesizes findings from cortical thickness studies, focusing on methodological approaches, variations in imaging sequences and study designs, including cross-sectional and longitudinal studies. Results: Studies using surface-based morphometry (i.e. SBM) and voxel-based morphometry (i.e. VBM) have reported inconsistent findings. Increased thickness is frequently observed in pain-processing regions, such as the somatosensory cortex, insula and anterior cingulate cortex reflecting hyperexcitability or maladaptive neuroplasticity. by contrast, cortical thinning has been noted in regions such as the orbitofrontal cortex, posterior cingulate cortex and visual cortex, suggesting neuronal loss or impaired cortical integrity. Differences between episodic and chronic migraine further highlight progressive structural changes associated with disease burden. Emerging evidence also suggests that preventive treatments, including calcitonin gene-related peptide monoclonal antibodies and botulinum toxin A, may reverse some of these cortical alterations, particularly in treatment responders. Conclusions: Cortical thickness analysis provides valuable insights into migraine pathophysiology, offering a potential biomarker for disease progression and treatment response. However, inconsistencies across studies highlight the need for standardized MRI protocols and larger longitudinal investigations to clarify the clinical relevance of cortical thickness changes in migraine.

6 January 2026 in Toxins
Verified
Journal Article
Open access
PDF file
BCBasit Ali Chaudhry
Basit Ali Chaudhry
Christopher Louis RobinsonChristopher Louis Robinson
Christopher Louis Robinson
ECEdoardo Caronna
Edoardo Caronna
FDFreda Dodd-Glover
Freda Dodd-Glover
AVAmrittej Singh Virk
Amrittej Singh Virk
SASait Ashina
Sait Ashina
Temporomandibular disorders (TMDs) are common musculoskeletal chronic orofacial pain conditions involving peripheral and central sensitization within trigeminal nociceptive pathways, manifesting as mechanical allodynia and functional impairment. Botulinum toxin type A (BoNT-A) has been explored as a treatment targeting both muscle hyperactivity and nociceptive modulation. Preclinical and clinical evidence demonstrate that BoNT-A reduces peripheral neurotransmitter release, neurogenic inflammation, and central neuronal excitability, leading to attenuation of mechanical allodynia in TMD models and patients. Clinical trials show modest and variable analgesic effects, with patients displaying sensory sensitization appearing to respond more favorably, though methodological heterogeneity limits definitive conclusions. Safety concerns related to muscle weakening, changes in bone density, and structural changes underscore the need for standardized protocols optimizing dosing and monitoring, in addition to prospective studies. These findings suggest that BoNT-A may serve as an adjunctive, mechanism-based therapy within multimodal TMD management. Future research should focus on standardized sensory phenotyping and trial design to clarify BoNT-A’s role in modulating central sensitization and improving patient outcomes.

1 April 2026 in Cephalalgia
Verified
Journal Article
Open access
ZHZahra Hakimzadeh
Zahra Hakimzadeh
BCBasit Ali Chaudhry
Basit Ali Chaudhry
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
RCRune Häckert Christensen
Rune Häckert Christensen
MAMessoud Ashina
Messoud Ashina
HAHåkan Ashina
Håkan Ashina
Background: Migraine aura reflects transient neurological disturbances attributed to cortical spreading depolarization (CSD), yet the upstream molecular events that promote or precipitate this phenomenon remain uncertain. Human pharmacological provocation models provide a controlled approach to identifying endogenous signaling pathways capable of triggering aura and thereby clarifying their mechanistic role in migraine pathogenesis. Methods: This systematic review was pre-registered in PROSPERO (ID: CRD420250636266) and conducted in accordance with the Synthesis Without Meta-Analysis (SWiM) guideline. PubMed and Embase were searched from database inception through January 1, 2026, without language restrictions, to identify experimental studies administering pharmacological agents to individuals with migraine with aura under controlled lab conditions. Two reviewers independently performed study selection, data extraction, and methodological assessment. Extracted variables included participant characteristics, study design, pharmacological trigger, dosing protocol, and the incidence, timing, and phenotype of provoked aura and headache. Because of substantial heterogeneity, findings were synthesized qualitatively. Results: Fourteen studies met inclusion criteria, examining seven pharmacological agents: calcitonin gene-related peptide (CGRP), levcromakalim (ATP-sensitive potassium (K ATP ) channels opener), glyceryl trinitrate (GTN), sildenafil, cilostazol, endothelin-1, and histamine. Across studies, aura induction occurred far less frequently than headache induction. CGRP provoked aura in 17 (32%) of 53 participants across three studies, with latencies ranging from 10 to 360 min. Pharmacological opening of vascular K ATP channels by levcromakalim elicited aura in 14 (27%) of 52 participants in randomized crossover trials, with onset between 20 and 120 min. Other agents produced minimal or no aura responses. Conclusions: Human pharmacological provocation provides a reproducible framework for dissecting molecular pathways that can trigger migraine aura. Current evidence implicates CGRP signaling and vascular ATP-sensitive potassium channel activation as the most plausible associated candidate pathways. However, standardized protocols and larger controlled studies are required to confirm these mechanisms and refine experimental models of aura biology. Trial Registration: PROSPERO (ID: CRD420250636266).

4 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HAHaidar Muhsen Al-Khazali
Haidar Muhsen Al-Khazali
RCRune Häckert Christensen
Rune Häckert Christensen
AMAnna Gudrun Melchior
Anna Gudrun Melchior
SASarra Al-Khazali
Sarra Al-Khazali
BCBasit Ali Chaudhry
Basit Ali Chaudhry
HAHåkan Ashina
Håkan Ashina
Background: Substance P is a vasoactive neuropeptide implicated in trigeminovascular signalling, but its causal role in initiating migraine attacks remains uncertain. We tested whether intravenous infusion of substance P triggers migraine attacks in people with migraine without aura.Methods: This was a randomised, double-blind, placebo-controlled, single-centre, two-way crossover study involving adults with migraine without aura. Participants received intravenous substance P (4·0 pmol/kg/min for 20 min) and isotonic saline (placebo) in random order, separated by a 1-week washout. Randomisation was generated by an independent hospital pharmacy using block randomisation (block size four; final participant by simple randomisation). Participants, investigators, care providers, and outcome assessors were masked to allocation. The primary outcome was incidence of a migraine attack without aura within 12 h after infusion. The primary analysis used McNemar’s test for paired outcomes. Safety outcomes included adverse events and hemodynamic measures. This study was pre-registered with ClinicalTrials.gov (Identifier: NCT06959004).Findings: Between May 13 and Aug 17, 2025, 66 individuals were assessed for eligibility; 21 were enrolled and randomised (18 female and three male); all completed both sessions. Migraine attacks occurred in 17 of 21 participants (81%) following substance P and two (10%) after placebo (p < 0·001). Median time to migraine onset was 20 min (IQR 20–30) after substance P, and median peak headache intensity (0–10 numeric rating scale) was 5 (IQR 3–6). The area under the curve for headache intensity scores over 12 h was greater after substance P than placebo (p < 0·001). Eight participants required acute headache medication after substance P versus two after placebo. No serious adverse events occurred.Interpretation: Intravenous substance P triggers migraine attacks in adults with migraine without aura, supporting a causal role for substance P-related signalling in attack initiation and motivating identification of this pathway as a potential therapeutic target.